Health Technology Assessment on Cervical Cancer Screening, 2000–2014

Abstract

Objectives: The aim of this study was to conduct a review of health technology assessments (HTAs) in cervical cancer screening to highlight the most common metrics HTA agencies use to evaluate and recommend cervical cancer screening technologies.Methods: The Center for Reviews and Dissemination (CRD), MedLine, and national HTA agency databases were searched using keywords (“cervical cancer screening” OR “cervical cancer” OR “cervical screening”) and “HTA” from January 2000 to October 2014. Non-English language reports without English summaries, non-HTA reports, HTAs unrelated to a screening intervention and HTAs without sufficient summaries available online were excluded. We used various National Institute for Health and Care Excellence (NICE) methods to extract key assessment criteria and to determine whether a change in screening practice was recommended.Results: One hundred and ten unique HTA reports were identified; forty-four HTAs from seventeen countries met inclusion criteria. All reports evaluated technologies for use among women. Ten cervical screening technologies were identified either as an intervention or a comparator. The most common outcome metric evaluated was diagnostic accuracy, followed by economic effectiveness. Additional outcome metrics such as the use of adjunct testing, screening intervals, and age-specific testing were commonly evaluated. Nearly one-third (fifteen of forty-four) of HTAs recommended a change in practice.Conclusions: This review highlights popular metrics used in HTAs for cervical cancer screening. Clinical and economic effectiveness metrics have been consistently assessed in HTAs, while the use of adjunct testing, screening intervals, and age-specific screening became increasingly prevalent from after 2007. Moreover, we observed an increase in optimized recommendations after 2007.

The lncRNA TDRG1 promotes cell proliferation, migration and invasion by targeting miR-326 to regulate MAPK1 expression in cervical cancer

“…Cervical cancer (CC) is the second leading cause of cancer-related mortality in female worldwide [1, 2]. According to relevant statistics, nearly 529,800 new cases are diagnosed worldwide annually [3], and the number of CC related death in developing countries are dramatically higher than developed countries [4]. Despite advanced progresses in therapeutic approaches including surgery, radiation and chemotherapy, individually or in combination, a considerable patients’ long-term survival rate still remains suboptimal due to recurrence and metastasis [5].…”

The New Biomarker for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC) Based on Public Database Mining

“…Connections between nodes represent the relationship between proteins. 4 BioMed Research International…”

“…Cervical cancers are a leading cause of mortality among women [1], especially in developing countries [2], and they are the second most common gynecological cancer type [3]. At the same time, a large number of patients are diagnosed with cervical cancer every year [4]. Among cervical cancers, the cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) kind account for 10-15% of all female cancer-related deaths and present the second-highest mortality behind breast cancer [5].…”

Reconstruction and analysis of the aberrant lncRNA‐miRNA‐mRNA network based on competitive endogenous RNA in CESC

“…1 Cervical cancer has an estimated incidence of 530 000 new cases and 270 000 deaths, annually. 2 Cervical squamous cell carcinoma (CESC) was responsible for 10-15% of all females' cancer-related deaths worldwide that contributed to the second highest number of deaths in female cancers, exceeded only by breast cancer. 3,4 At the time of diagnosis, 80% patients have already progressed into invasive cancer stages of cervical cancer.…”